Please upgrade your browser.
Dr Martin Voss, (Memorial Sloan Kettering Cancer Centre, New York City, USA) talks to ecancertv at ASCO GU 2015 on part 1 of the DART study, a phase II randomised trial using dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma.
Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immunotherapy was found to be effective in patients with the most common form of kidney cancer.
Those impressive reductions in death are still only likely to mean that Cometriq gave patients, on average, a few more months of life.
Axl plays multiple roles in tumourigenesis in several cancers. Here we evaluated the expression and biological function of Axl in renal cell carcinoma (RCC).
Argos is developing a therapy to treat metastatic renal cell carcinoma (mRCC) and hit the enrollment goal of 450 randomized patients. This is a Phase 3 trial, meaning it is one of the last major steps a drug developer takes before submitting an application with the U.S. Food and Drug Administration.
The 13-year total for “Lift for Life” is now more than $1.12 million. More than 100 members of the Nittany Lion football team participated in Saturday's Lift For Life.
Patients benefit twice from the new technique: during the operation itself, the risk of bleeding and complications is lower. In the long term, renal function is preserved and there are no long-term consequences of renal impairment.
Project Title: "Interrogation of the Sorbitol Pathway in VHL-Independent HIF driven Renal Cell Carcinomas"
Little is known about the biological behavior of Xp11.2 translocation renal cell carcinomas (RCCs) as few clinical studies have been performed using a large sample size.
Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma
The renin-angiotensin system may play a role in carcinogenesis. The purpose of this study was to evaluate the impact of angiotensin system inhibitors (ASI) on outcomes in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era.
|Powered by NeonCRM|